

16th
ANNUAL
2024
CONFERENCE

NNDC ANNUAL CONFERENCE ATTENDEE INFORMATION

**Bridging Science, Technology and Compassion:
Innovations in Mental Health Care
Salt Lake City, September 11-12, 2024**

*In collaboration with this year's host, the University of Utah
Huntsman Mental Health Institute.*



NATIONAL NETWORK *of*
DEPRESSION CENTERS

Table of Contents

Welcome to the 2024 NNDC Annual Conference.....	1
Conference Sponsors.....	2
NNDC Board of Directors.....	3
NNDC Staff.....	4
Agenda.....	5-6
Speaker Biographies.....	7-9
NNDC Members.....	10
Myriad Symposium Information.....	11-13
Learner Information.....	14-16
How to Obtain Your Certificate.....	16
2024 Poster Submissions.....	17-20
Alumni House Layout + Map.....	21-22
Upcoming Events.....	23
Connect with us!.....	24



Welcome to the 2024 NNDC Annual Conference!

Esteemed guests, colleagues, and friends,

It is with great pleasure that we welcome you to the 2024 NNDC Annual Conference. This year's theme is "**Bridging Science, Technology, and Compassion: Innovations in Mental Health Care**" and we're excited to discuss the evolving role technology plays in our work. We're thrilled to gather and explore the groundbreaking advancements and innovative approaches that are transforming the landscape of mental health care.

This year's conference title embodies our mission to merge the rigorous methodologies of science, the transformative power of technology, and the essential human element of compassion. We are here to discuss, learn, and collaborate on innovative solutions that address the complexities of mental health in a holistic and inclusive manner.

With a robust agenda, we will hear from leading experts in the fields of neuroscience, psychiatry, psychology, and technology. We look forward to delving into cutting-edge research, examining new therapeutic technologies, and sharing best practices that have the potential to significantly improve the lives of those affected by mental health conditions.

This conference is a platform for building connections, fostering collaboration, and inspiring action. We are here to challenge conventional boundaries, question existing paradigms, and create a future where mental health care is accessible, effective, and compassionate for all.

We encourage you to engage actively, share your insights and reflect on the diverse perspectives that each of our participants brings. Together, we can pave the way for innovations that bridge science, technology, and compassion, making a tangible difference in mental health care.

Thank you for joining us on this important journey. Let's work together to transform these innovations in order to bring hope, healing, and humanity to all who need it.

In learning and collaboration,



Mark Frye, MD Sagar Parikh, MD



Mark Frye, MD Sagar Parikh, MD



From the NNDC Team

On behalf of the entire NNDC Team, we are pleased to welcome you to Salt Lake City, Utah for the 16th Annual Conference! Each year the conference program highlights the ways the NNDC is uniquely positioned to improve diagnosis and treatment of mood disorders by facilitating knowledge sharing across the nation and expediting next-generation research initiatives – and this year's program is no exception.

Our members are engaging in some of the most innovative and exciting innovation in the field, and the Annual Conference is a great way to connect over that work. We hope your time here is insightful and allows you to create connections to draw upon for years to come. Thank you for joining us and welcome to Salt Lake City!

Thank you to our 2024 Sponsors!

Platinum Sponsor



Silver Sponsors



Supporting Sponsor



NNDC Board of Directors

Executive Committee of the Board

Mark Frye, MD (President) • Mayo Clinic
Jair C. Soares, MD, PhD (Vice President) • University of Texas Health Science Center at Houston
Stephen Strakowski, MD (Treasurer) • Indiana University
Melissa DelBello, MD, MS (Secretary) • University of Cincinnati & Lindner Center of HOPE
John F. Greden, MD (Founding Chair) • University of Michigan Eisenberg Family Depression Center
J. Raymond DePaulo, Jr, MD (Immediate Past President) • The Johns Hopkins Mood Disorders Center
Olusola Ajilore, MD, PhD (Member-at-Large) • University of Illinois at Chicago
C. Neill Epperson, MD (Member-at-Large) • University of Colorado Anschutz Medical Campus
Faith Gunning, PhD (Member-at-Large) • Weill Cornell Medicine
Stuart Charney, RPH, JD (Board Advisor) • NNDC Advisory Council

Board Members

Caleb Adler, MD • University of Cincinnati & Lindner Center of HOPE
Jorge Almeida, MD, PhD • University of Texas Austin & The Center for Youth Mental Health
Katherine Burdick, PhD • Brigham & Women's Hospital, Partners HealthCare - Harvard Medical School
David Casey, MD • University of Louisville
Susan K. Conroy, MD, PhD • Indiana University
William Coryell, MD • University of Iowa
Mario Cristancho, MD • University of Pennsylvania
Dimitry Davydow, MD, MPH, FACLP • University of Florida
Joao de Quevedo, MD, PhD • University of Texas at Houston, McGovern Medical School
Marc Dubin, MD, PhD • Weill Cornell Medical College
Rif El-Mallakh, MD • University of Louisville Depression Center
Jay Fournier, PhD • The Ohio State University
Fernando Goes, MD • Johns Hopkins Medicine
Adriana Hermida, MD • Emory University
Richard Holbert, MD • University of Florida
Kay Redfield Jamison, PhD • Johns Hopkins University Mood Disorders Center
Anand Kumar, MD, MHA • University of Illinois at Chicago
Scott Langenecker, PhD • The Ohio State University
Brian Mickey, MD, PhD • University of Utah Huntsman Mental Health Institute
Jeffrey Newport, MD, MS • University of Texas Austin & The Center for Youth Mental Health
Sagar Parikh, MD, FRCPC • University of Michigan Eisenberg Family Depression Center
Mark Rapaport, MD • University of Utah Huntsman Mental Health Institute
Natalie L. Rasgon, MD, PhD • Stanford University
Scott L. Rauch, MD • McLean Hospital, Partners HealthCare - Harvard Medical School
Patricio Riva Posse, MD • Emory University
Moirá Rynn, MD • Duke University
Alan F. Schatzberg, MD • Stanford University
Christopher Schneck, MD • University of Colorado Anschutz Medical Campus
Michael Thase, MD • University of Pennsylvania
Carolyn Turvey, PhD • University of Iowa
Jennifer L. Vande Voort, MD • Mayo Clinic
To be determined • Duke University
To be determined • Universidad Autónoma de Nuevo León
To be determined • Universidad Autónoma de Nuevo León

Associate Member Leadership

Eric Achtyes, MD, MS • Western Michigan University Homer Stryker M.D. School of Medicine
Lena Brundin, MD, PhD • Van Andel Institute
Heather Flynn, PhD • Florida State University
Scott Gaynor, PhD • Western Michigan University
Louis Nykamp, MD • Pine Rest Christian Mental Health Services
Erika Saunders, MD • Penn State Milton S. Hershey Medical Center
Patrick Sullivan, MD, FRANZCP • University of North Carolina at Chapel Hill
Nagy Youssef, MD, PhD • Michigan State University

About the Organization + NNDC Staff Members

The NNDC is a national network of world-class institutions and collaborators united to lift the burden of depression, bipolar and other mental health conditions to advance people's overall wellness. The organization works to transform people's lives through innovations in research, driving care solutions and advancing collective community impact.

Founded in 2008, the NNDC has since grown to 27 members representing the top and most well-regarded psychiatry programs in the nation. Learn more at www.nndc.org.

Leadership + Contact Information



Dr. Matt Samocki
Executive Director
✉ msamocki@nndc.org



Brad Hovermale
Director of Operations
✉ bhovermale@nndc.org



Courtney Soule
Director of Membership, Development
+ Public Relations
✉ csoule@nndc.org



Mary Laffey
Task Group Manager +
Strategy Lead
✉ mlaffey@nndc.org



Rob Vallentine
Strategic Business Advisor
✉ rvallentine@nndc.org



Sagar Parikh, MD
Medical Director



Bailey Rann
Research + Media Specialist
✉ brann@nndc.org

TIME	ITEM	TOPIC	SPEAKER	LOCATION
7:30-8:15 AM	Myriad Genetics sponsored Non-CME and Non-Promotional Symposium Independent of the Conference	Psychiatric Pharmacogenomic Testing Exposed: Evidence, Limitations, and the Future of Implementation	Boadie Dunlop, MD, MS Emory University School of Medicine Carson Felkel, MD, MBA, FAPA, Bon Secours Health System Eric Monson, MD, PhD University of Utah Facilitator: Ryan Griggs, PhD, MS, Myriad Genetics	OC Tanner Ballroom C
7:30-8:30 AM	Registration, Breakfast	-	-	OC Tanner Ballroom B
8:30-9:00 AM	Welcome	Welcome Address / NNDC Administrative Updates	NNDC Leadership	OC Tanner Ballroom B+C
9:00-9:25 AM	Symposium: Challenges in Disseminating Psychosocial Treatments	Bipolar Education Project: One Approach to Making Psychosocial Treatments More Accessible (20 min talk, 5 min Q&A)	Chris Schneck, MD University of Colorado Anschutz	OC Tanner Ballroom B+C
9:25-9:50 AM		Validate, then Promulgate: Challenges in Disseminating Interpersonal and Social Rhythm Therapy (IPSRT)	Ellen Frank, PhD University of Pittsburgh	
9:50-10:15 AM		Using AI as a Therapy Supervisor in Training Therapists more Efficiently	Veronica Perez-Rosas, PhD University of Michigan	
10:15-10:30 AM		Panel Discussion with Audience Feedback (15 min Q&A)	Moderator: Sagar Parikh, MD, FRCPC, University of Michigan NNDC Medical Director	
10:30-11:00 AM	Break	-	-	OC Tanner A+B+C
11:00-11:30 PM	Mini-Symposia 1: Novel Treatment Updates	New Findings with the Stanford Neuromodulation Therapy (25 min , 5 min Q&A)	Nolan Williams, MD Stanford University	OC Tanner Ballroom B+C
11:30-12:00 PM		Propofol for Treatment Resistant Depression	Brian Mickey, MD, PhD University of Utah	OC Tanner Ballroom B+C
12:00-12:45 pm	Lunch	-	-	OC Tanner A+B+C
12:45-2:00 PM	Poster Session	-	-	OC Tanner Ballroom A

Agenda: Thursday, September 12, 2024, continued

TIME	ITEM	TOPIC	SPEAKER	LOCATION
2:00-3:00 PM	Plenary Talk	Psychiatry and AI: Should Bots take over Empathy? (45 min, 15 min Q&A)	Jodi Halpern, MD, PhD, University of California, Berkeley	OC Tanner Ballroom B+C
3:00-3:30 PM	Break	-	-	OC Tanner A+B+C
3:30-4:00 PM	Mini-Symposia 2: Diversity and Equity: Women's Mental Health	The Role of the Hypothalamic-Pituitary-Adrenal Axis in Depression Across the Female Reproductive Lifecycle: Differential Mechanisms, Differential Treatments (25 min, 5 min Q&A)	Sandra Weiss, PhD UCSF	OC Tanner Ballroom B+C
4:00-4:30 PM		Differences in Treatment of Mood Disorders Among Women from Diverse Backgrounds: Challenges and Solutions (25 min, 5 min Q&A)	Robert Ammerman, PhD, ABPP University of Cincinnati	OC Tanner Ballroom B+C
4:30-4:50 PM	Hot Topics	Interplay Between Mitochondria and Cognition in BD (15 min, 5 min Q&A)	Giselli Scaini, PharmD, PhD UT Houston	OC Tanner Ballroom B+C
4:50-5:10 PM		Beyond Depression: Searching for Genetic Factors Linked to Suicide (15 min, 5 min Q&A)	Anna Docherty, PhD University of Utah	OC Tanner Ballroom B+C
5:10-5:30 PM		Racial Discrimination, Neural Connectivity, and Epigenetic Aging Among Black Women (15 min, 5 min Q&A)	Fani Negar, PhD Emory University	OC Tanner Ballroom B+C
5:30-6:30 PM	NNDC Networking Happy Hour	-	-	OC Tanner A+B+C
6:30-8:30 PM	Dinner + Award Ceremony	-	-	OC Tanner Ballroom B+C

Speaker Biographies

Plenary Speaker: Jodi Halpern, MD, PhD

Jodi Halpern MD, PhD, Chancellor's Chair and Professor of Bioethics at UC Berkeley, is an international leader on empathy in healthcare and the ethics of innovative technologies including AI, gene editing and neurotechnology. Halpern's book, *From Detached Concern to Empathy: Humanizing Medical Practice* catalyzed a wave of change in medicine. Her book, *Remaking the Self in the Wake of Illness* (expected 2024) illuminates post-traumatic growth. Her newest project *Engineering Empathy* examines AI and therapeutic relationships. Halpern co-founded and co-directs the Kavli Center for Ethics, Science and the Public and the Berkeley Group on the Ethics and Regulation of Innovative Technologies. Halpern advises NGOs, companies, and governments. She speaks in settings ranging from the Davos World Economic Forum to NPR to CBS News. Halpern received the Guggenheim 2022 Award in Medicine and Health. See more at Jodihalpern.com



Robert Ammerman, PhD

Professor of Pediatrics Cincinnati Children's Hospital Medical Center

Dr. Ammerman is Professor of Pediatrics with a CCRF Endowed Chair. He is Scientific Director of Every Child Succeeds, a home visiting program for new mothers and young children. He is the co-developer of Moving Beyond Depression, a CBT treatment program for low-income mothers.



Anna Docherty, PhD

Associate Professor of Psychiatry, University of Utah

Dr. Docherty examines genetic risk and resilience in the context of mental health, with a focus on leveraging quantitative genomics to inform treatment and prevention of severe psychiatric outcomes. She has led several NIH-funded research projects focused on improving our understanding of biological risk of psychiatric outcomes and suicide across global populations.

A current NIMH R01 involves multi-ancestry genome-wide association studies (GWAS) and polygenic risk modeling of population-based suicide death in the U.S. Another NIMH R01 involves the development of a brain tissue and blood biobank and postmortem suicide death based in Delhi, India. And another NIMH R01 leverages data from 41 global institutions to improve our models of psychiatric mortalities. Other NIH-funded projects include efforts to integrate health record data and exposure data across the lifespan with genomic metrics of health and disease.

Dr. Docherty helps lead global research and capacity-building as a member of the Steering Committee of the Psychiatric Genomics Consortium (PGC), and as Co-Chair of the Suicide Working Group of the PGC. She is a contributing PI to several other PGC working groups, with a focus on cross-disorder risks (MDD, Anxiety, Schizophrenia, PTSD, ADHD, Substance Use Disorders, Cross Disorders, CNV, ECT response, and the Latin American Genomics Consortium). She is heavily involved in cross-disorder efforts to map the latent genetic structure of psychiatric symptoms associated with the highest rates of mortality.



Dr. Docherty is Assistant Director of the Clinical and Translational Sciences Research Institute (CTSI) at the University of Utah, focused on enhancing sequencing, stem cell, and biorepository capacities for the SOM. She is Site PI and Associate Course Director for the NIH R25 annual quantitative workshop, Advanced Statistical Training for Imaging and Genetics, for rising stars in imaging and genetics. And with interests in public policy and bioethics, Dr. Docherty serves as Co-Chair of the Ethics & Public Policy Committee of the International Society of Psychiatric Genetics.

Ellen Frank, PhD

Distinguished Professor Emeritus of Psychiatry, University of Pittsburgh School of Medicine

Ellen Frank is Chief Scientific Officer and Co-founder of Health Rhythms, Inc. a digital start-up focused on using the commercial smartphone to measure behavior relevant to mental health and using that information to provide clinicians and health systems and pharmaceutical companies with something we have never had before: continuous objective measurement of mental health status.

Ellen also holds the rank of Distinguished Professor Emeritus of Psychiatry and Psychology at the University of Pittsburgh School of Medicine. She is best known for the development and testing of a series of somatic and psychosocial treatment approaches for major depression and bipolar disorder. Interpersonal and social rhythm therapy (IPSRT), originally designed and tested as an individual treatment for adults with bipolar disorder, has been adapted to a range of other conditions in adults and adolescents and to both inpatient and outpatient group settings. The rhythm-based theoretical model that underpins IPSRT now forms the basis for the smartphone technology that she and her Health Rhythms colleagues have developed for the continuous passive measurement of illness severity in individuals with mood disorders.

Ellen is a member of the National Academy of Medicine, has served on the FDA Psychopharmacologic Drugs Advisory Panel, as a member of the National Advisory Mental Health Council and as a member of the Mood Disorders Workgroup of the APA Task Force on DSM-5. She has published more than 475 peer-reviewed papers and over 125 books and book chapters, most of which focus on recurrent mood disorders.



Negar Fani, PhD, ABPP

Associate Professor, Emory University

Negar Fani, PhD, ABPP, is a clinical neuropsychologist, and Associate Professor at the Department of Psychiatry and Behavioral Sciences at Emory University. She has been a co-investigator in the longest running study of trauma in the nation, the Grady Trauma Project for >17 years. Her multimodal research (functional and structural MRI, psychophysiology, neuropsychological testing, EEG) centers around investigating the ways in which trauma and marginalization, including racism, affects the brain, body and behavior, with a particular focus on attentional processes. She augments interventions with novel technologies (e.g., vibroacoustic feedback, temporal interference brain stimulation) to make these interventions more effective and accessible to diverse populations.



Brian Mickey, MD, PhD

Professor of Psychiatry, University of Utah

Brian J. Mickey is Professor of Psychiatry at the University of Utah. He studied physics and biology at the University of Washington, Seattle, then completed his MD and PhD in Neuroscience at the University of Michigan, Ann Arbor. In 2015, he moved to the University of Utah, where he is a faculty member in Psychiatry, Neuroscience, Biomedical Engineering, and Anesthesiology. Dr. Mickey is a clinical psychiatrist who specializes in treatment-resistant mood disorders and neuromodulation therapies. His research focuses on understanding how limbic and prefrontal circuits are dysregulated in psychiatric disorders, and developing circuit-targeted interventions that return the brain to a healthy state.



Veronica Perez-Rosas, PhD

Assistant Professor, Texas State University

Veronica Perez-Rosas is an Assistant Professor at Texas State University. Previously, she was a research scientist at the University of Michigan. She received her Ph.D. in Computer Science and Engineering from the University of North Texas in 2014. Her research interests include natural language processing, machine learning, affect recognition, and multimodal processing of human behavior. Her research focuses on developing computational methods to analyze, recognize, and predict human behaviors during social interactions. She has authored papers in leading conferences and journals in Natural Language Processing and Multimodal Processing, has mentored numerous students in these research areas, and has served as workshop chair or area chair for multiple international conferences in the field.



Giselli Scaini, PhD

Assistant Professor, UTHealth Houston


Giselli Scaini, PhD, is an assistant professor in the Faillace Department of Psychiatry and Behavioral Sciences and a translational researcher in the field of biological psychiatry. Her research focuses on understanding the role of redox modulations and mitochondrial dysfunction in mental illness, especially in mood disorders, with the ultimate goal of developing better diagnostic tools, personalized treatments, and an enhanced quality of life for patients. Dr. Scaini received her Master's degree and her PhD in Health Science from the University of Southern Santa Catarina (UNESC, Brazil). As an Assistant Professor, she currently collaborates with basic and clinical investigators on the search for cellular and molecular underpinnings of severe mental illnesses. She has published over 140 peer-reviewed articles and received awards for her research work from multiple scientific societies.



Christopher Schneck, MD

Professor of Psychiatry, Adult Division Director, Marsico Endowed Chair for Excellence and Medical Director, Johnson Depression Center at the University of Colorado Anschutz

Christopher Schneck, MD, is Professor of Psychiatry, the Adult Division Director for the Department of Psychiatry, and holds the Marsico Endowed Chair for Excellence. He is the Medical Director of the Helen and Arthur E Johnson Depression Center and the CU Medicine Bipolar Program. Dr. Schneck's primary area of clinical interest is in the treatment of complex mood disorders, both in specialty clinics and integrated care settings. His research over the last 25 years has focused on multiple aspects of bipolar disorder, including rapid cycling bipolar disorder in adults as well as assessment and management of adolescents with bipolar disorder. His most recent research has investigated Family Focused Therapy as an early intervention for adolescents at high risk for bipolar disorder. Dr. Schneck spends considerable time teaching residents and has won many awards for his teaching and his clinical care of patients.



Sandra Weiss, PhD, DNSc

Professor and Eschbach Endowed Chair, University of California, San Francisco

Dr. Weiss is Professor and Eschbach Endowed Chair in the Department of Community Health Systems at the University of California, San Francisco (UCSF) as well as Director of the UCSF Stress and Depression Laboratory. She has a PhD in Biological and Developmental Psychology from University of California at Berkeley and a DNSc (with a specialty in family psychiatry) from University of California at San Francisco. Dr. Weiss' program of research focuses on causes, underlying mechanisms, and effects of depression, stress, and mood-related symptoms, especially among women during pregnancy and the postpartum. She has an interest in mechanisms associated with dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Her research has identified effects of glucocorticoid exposure and women's HPA axis alterations on their depression and suicide risk as well as differential types of cortisol dysregulation in anxiety versus depression. Dr. Weiss has over 30 years of NIH funded research and has served as the chair and member of multiple scientific panels for the NIH Center for Scientific Review. Among multiple leadership roles, she has been the Associate Provost for Research at the University of California's Office of the President (responsibility for the 10-campus system), Executive Director of the Health Care Consortium in the San Francisco Bay Area, and Co-Director of the UCSF Depression Center.




Nolan Williams, MD

Associate Professor of Psychiatry and Behavioral Sciences, Director, Brain Stimulation Laboratory, Director, Interventional Psychiatry Clinical Research Department of Psychiatry and Behavioral Sciences at Stanford University

Nolan Williams, MD, is an Associate Professor within the Department of Psychiatry and Behavioral Sciences and Director of the Stanford Brain Stimulation Lab. He has a broad background in clinical neuroscience and is triple board-certified in general neurology, general psychiatry, and behavioral neurology & neuropsychiatry. Themes of his work include examining the use of spaced learning theory in the application of neurostimulation techniques, development and mechanistic understanding of rapid-acting antidepressants, and identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. His work resulted in an FDA clearance for the world's first non-invasive, rapid-acting neuromodulation approach for treatment-resistant depression. He has published papers in high-impact peer-reviewed journals, including Nature Medicine, Nature Mental Health, Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. Results from his studies have gained widespread attention in Science and NEJM Journal Watch and have been featured in multiple news outlets, including TIME, US News & World Report, Newsweek, Scientific American, ABC, NBC, CBS, NPR, and more. Dr. Williams received two NARSAD Young Investigator Awards in 2016 and 2018, as well as the 2019 Gerald L. Klerman Award. He was honored with the Stanford University Chairman's Award for Advancing Science in 2019. In 2020, he received the National Institute of Mental Health Biobehavioral Research Award for Innovative New Scientists as well as the One Mind Bipolar Research Award. In 2020, 2021 and 2022, he received the BBRF Leading Research Achievements Awards, and in 2024, he received the A.E. Bennett Award from the Society of Biological Psychiatry.



NNDC Member Sites



The National Network of Depression Centers is comprised of major academic medical centers from around the country. By uniting our Centers of Excellence and our Associate Members in a collaborative network, the strongest players in the field grow stronger. The NNDC combines unparalleled expertise and fully leverages available resources to advance state-of-the-science in the field of mood disorders.

CENTERS OF EXCELLENCE

- Brigham & Women’s Hospital - Harvard Medical School
- Duke University
- Emory University
- Indiana University
- Johns Hopkins University Medicine Mood Disorders Center
- Mayo Clinic
- McLean Hospital - Harvard Medical School
- The Ohio State University
- Stanford University
- Universidad Autonoma de Nuevo Leon (UANL)
- University of Cincinnati & Lindner Center of HOPE
- Helen and Arthur E. Johnson Depression Center at the University of Colorado Anschutz Medical Campus
- University of Florida Health, Mood Disorders Program
- University of Illinois at Chicago
- University of Iowa Mood Disorders Center
- University of Louisville Depression Center

- University of Michigan Frances and Kenneth Eisenberg and Family Depression Center
- University of Pennsylvania
- Dell Medical School at The University of Texas at Austin
- The University of Texas Health Science Center at Houston
- University of Utah
- Weill Cornell Medicine

ASSOCIATE MEMBERS

- Florida State University College of Medicine
- Michigan State University & Pine Rest Christian Mental Health Services
- Penn State Health Milton S. Hershey Medical Center
- University of North Carolina at Chapel Hill School of Medicine
- Van Andel Institute, Western Michigan University Homer Stryker M.D. School of Medicine & Western Michigan University

Myriad Genetics sponsored Non-CME and Non-Promotional
Symposium Independent of the NNDC Annual Conference

Psychiatric Pharmacogenomic Testing Exposed Evidence, Limitations, and Future Implementation

This non-CME, non-promotional breakfast symposium sponsored by Myriad Genetics will delve into key questions related to the evidence, limitations, and future of implementing psychiatric pharmacogenomic testing for depression as a personalized medicine tool. A panel of three psychiatrists with different clinical and research backgrounds will weigh in on a series of illuminating questions in a moderated question and answer format.

7:30am MT | Thursday | September 12, 2024 | Ballroom C | Alumni House



Eric Monson, MD, PhD

Carson Felkel,
MD, MBA, FAPA

Boadie Dunlop, MD, MS

Moderator
Ryan Griggs, PhD, MS

Give us your
feedback!



[Anonymous Evaluation Link](#)

Scroll for more information about
the symposium!

Myriad Genetics Sponsored Non-CME and Non-Promotional Symposium Independent of the NNDC Annual Conference

TITLE

Psychiatric Pharmacogenomic Testing Exposed: Evidence, Limitations, and the Future of Implementation

FORMAT

Non-CME Breakfast Symposium 7:30am-8:15am on Thursday, September 12, 2024. Moderated panelist Q&A format. One moderator and three panelists. Goal is to develop a panel with diverse backgrounds and research/practice experience that are utilizing or have familiarity with pharmacogenomic testing for psychiatric conditions such as depression. Moderator to provide warm welcome, introduce the session format/trajectory and panelists, and deliver 3-5-minute introduction on pharmacogenomic testing as a tool in depression treatment including level setting the audience on terminology/definitions. Moderator intro followed by targeted questioning of the three panelists. Moderator to close with brief outro. Minimal slides will accompany the session with objectives, questions, key bullet points, evidence overview, supporting material, etc. Session to last 45 minutes with potential extension by 10 minutes (8:15-8:25am) during the room changeover to continue audience Q&A discussion if the discussion is lively AND this does not interrupt the room changeover.

DESCRIPTION OF THE PROGRAM

Pharmacogenomics is an emerging field aiming to improve pharmacological treatment in various therapeutic areas such as cancer, cardiovascular disease, and psychiatry. For example, pharmacogenomic testing has the potential to provide greater precision for depression treatment by identifying clinically relevant variations in genes related to medication metabolism (pharmacokinetics) and/or response (pharmacodynamics). Organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenomics Working Group (DPWG), U.S. Food and Drug Administration (FDA), American Psychiatric Association (APA), Canadian Network for Mood and Anxiety Treatments (CANMAT), U.S. Department of Veterans Affairs / Department of Defense (VA/DoD), and International Society of Psychiatric Genetics (ISPG) have published guidelines, reviews, tables, or statements related to the clinical use of pharmacogenomic testing for medications commonly used to treat depression and other mental health conditions. In patients with major depressive disorder, numerous prospective trials have been conducted and published in peer-reviewed journals, comparing treatment outcomes for patients whose clinicians had access to the results from multi-gene pharmacogenomic testing panels (aka "PGx tools") to a control condition where patients were treated 'as usual' by their clinician without pharmacogenomic test results. Over ten meta-analyses of these PGx tool trials have utilized various methodologies to analyze the clinical utility of pharmacogenomic testing in depression, identifying significantly improved remission rates (~1.4 risk ratio). However, there is still no consensus on the use of pharmacogenomic testing in psychiatry, perhaps due to perceived limitations in the evidence, lack of education/awareness, or concerns about the cost:benefit ratio. Without definitive clinical practice guidelines detailing who may benefit from pharmacogenomic testing and/or when testing may be appropriate, clinicians and patients hoping to combat the increasing prevalence of depression and the trial-and-error approach to its treatment are left to educate themselves on the appropriate implementation of personalized medicine tools such as pharmacogenomic testing.

This non-promotional breakfast symposium will delve into key questions related to the evidence, limitations, and the future of implementing psychiatric pharmacogenomic testing for depression as a personalized medicine tool. A panel of three psychiatrists with different clinical and research backgrounds will weigh in on a series of illuminating questions in a moderated question and answer format.

Myriad Genetics Sponsored Non-CME and Non-Promotional Symposium Independent of the NNDC Annual Conference

PANELISTS

Boadie Dunlop, MD, MS

**Professor of Psychiatry and Behavioral Sciences, Director of Mood and Anxiety Disorders Program
Emory University School of Medicine**

Dr. Boadie Dunlop is a Professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine. He graduated from Mayo Medical School in 1997, completed his Residency in Psychiatry at Emory in 2001, and earned a Master of Science in Clinical Research at Emory in 2012. He currently serves as the Co-Director of the Emory Center for Psychedelics and Spirituality, as well as Director of Outpatient Programs and the Mood and Anxiety Disorders Program in the Department of Psychiatry, and as Medical Director of the Emory Healthcare Veterans Program. His clinical research program is focused on the neurobiology, psychopharmacology, and personalized treatment of major depression, anxiety disorders, and post-traumatic stress disorder. He has served as an investigator for more than 70 NIH- and industry-funded clinical studies of medication, psychotherapy, and their combination for the treatment for these conditions, including trials evaluating MDMA and psilocybin for PTSD and major depression. Dunlop has authored one book, twelve book chapters, and over 130 research papers in psychiatry and is a leader in the area of medication-assisted psychotherapy. He also provides supervision and lectures in psychopharmacology for Emory Psychiatry residents.

Carson Felkel, MD, MBA, FAPA

Medical Director for Behavioral Health, Bon Secours Health System

W. Carson Felkel II, MD, FAPA, is a Board-Certified Adult and Child and Adolescent Psychiatrist who leads behavioral health for Bon Secours Health System in Greenville, SC. He is an expert in creating behavioral health systems of care to improve quality, reduce the cost of care, and increase patient and provider satisfaction. He completed his training at Wake Forest Baptist Health, where he served as chief resident and chief fellow.

Eric Monson, MD, PhD

Assistant Professor, Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of Utah

Dr. Eric Monson obtained his undergraduate degree in biological engineering at Utah State University where he met his exceptional wife, Alison. During undergrad, he worked in a genetics lab researching autism and eventually matriculated to the University of Iowa for a combined MD/PhD program. He earned his PhD in computational genetics under Dr. Virginia Willour investigating the genetic underpinnings of suicidal behavior and bipolar disorder, which resulted in his passion for psychiatry. His collaborations with Dr. Hilary Coon at the University of Utah led to matching in a psychiatry residency research track, allowing his family, now including three children, to move back to Utah. He completed residency and fellowship training in adult and child and adolescent psychiatry, respectively, at the University of Utah, also serving as chief resident and obtaining a trauma certificate. Dr. Monson is currently a tenure-track assistant professor in the department of psychiatry, division of child and adolescent psychiatry at the University of Utah with an adjunct appointment in the department of pediatrics. His research focuses on the genetic and clinical factors involved in youth suicide with an emphasis on the intersection of psychological trauma and suicide death.

MODERATOR | Ryan Griggs, PhD, MS

Senior Medical Science Liaison, Myriad Genetics

As a Senior Medical Science Liaison with Myriad Genetics Mental Health, Ryan supports pharmacogenomic testing for mental health care by serving as a clinical and scientific resource for clinicians and fostering collaborations with the research and healthcare communities. Ryan helps providers utilize pharmacogenomic testing for their patients by delivering educational presentations and consulting on the interpretation of specific patient reports. Prior to Myriad, Ryan worked in drug discovery at Merck, taught at several academic institutions, and led a diverse team of international neuroscientists as a postdoctoral researcher. Ryan has a master's degree in Biotechnology from the University of Pennsylvania and a doctorate in Neurophysiology from the University of Kentucky. Ryan enjoys playing sand volleyball and spending time with his wife, two young children, and Waylon the dog in Dayton, OH.

Learner Notification

National Network of Depressions Centers
2024 NNDC 16th Annual Conference
September 12, 2024
Salt Lake City, Utah

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and National Network of Depressions Centers. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Professions in scope for this activity are listed below.

Amedco Joint Accreditation Provider Number: 4008163

Physicians

Amedco LLC designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists

This course is co-sponsored by Amedco and National Network of Depressions Centers. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists.



Amedco maintains responsibility for this program and content. Maximum of 7.25 hours.

The following state boards accept courses from APA providers for Counselors: AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, MD, ME, MO, NC, ND, NH, NE, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY

MI: No CE requirements.

*OK: Accepts APA credit for live, in-person activities but not for ethics and/or online courses.

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WDC, WI, WY

AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.

MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (held outside NY ONLY), OK*, OR, SC, UT, WA, WI, WY

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

Social Workers

As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.

Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. ASWB Content Level: Intermediate/Advanced. Social workers completing this course receive up to 7.25 continuing education credits.



ASWB approved continuing education

Learner Notification

Social Workers

The following state boards accept courses offering ASWB ACE credit for Social Workers: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NC, ND, NE, NH, NM, NV, OH, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WI, WV*, WY

*OK: Accepts ASWB ACE for live, in-person activities but not for ethics and/or online courses.

*WV: Accepts ASWB ACE unless activity is held live in West Virginia.

The following state boards accept courses offering ASWB ACE credit for Counselors: AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, MA, MD, ME, MO, ND, NE, NM, NH, NV, OK*, OR, PA, TN, TX, UT, VA, WI, WY

MI: No CE requirement

The following stateboards accept courses offering ASWB ACE credit for MFTs: AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, MD, ME, MO, NC, NE, NH, NM, NV, OK*, OR, PA, RI, TN, TX, UT, VA, WI, WY

AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted. MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review. MI: No CE requirement.

The following state boards accept ASWB ACE credit for Addictions Professionals: AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

Objectives

1. Gain insight into emerging systems and individual solutions related to mood disorder challenges.
2. Obtain new knowledge about the latest research about the use of artificial intelligence in psychiatry, exploring challenges in disseminating psychosocial treatments, novel treatment updates, diversity and equity in women's mental health and hot topics in psychiatry related to depression and mood disorders.
3. Learn, discuss, and explore opportunities to collaborate on initiatives designed to improve outcomes for people suffering from depression and mood disorders.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Yamile Acosta	NA
Robert Ammerman	NA
Laura Cabrera	NA
Paul Carlson	NA
Anna Docherty	NA
Joanna Douka	NA
Negar Fani	NA
Ellen Frank:	Psychiatric Assessments, Inc:Stock Shareholder (self & spouse Minerva Neurosciences:Stock Shareholder (spouse)
American Psychological Association Press (self):	Other
Jodi Halpern	NA
Brad Hovermale	NA
Becky Kinkead	NA
Christina Klein	NA
Mary Laffey	NA
Erin McGlade	NA
Brian Mickey:	LivaNova, Health Rhythms, Compass Pathways,Abbott:Research Grant Site, Principal Investigator InsideEdge:Consultant
Leslie Miller	NA
Bobby Nix	NA

Learner Notification

Disclosure of Conflict of Interest, continued

Name	Commercial Interest:Relationship
Sagar Parikh: Otsuka, Boehringer Ingelheim: Consultant, Aifred, Janssen:Scientific/Medical Advisory Board Member, Mensante: Stock Shareholder, Compass:Research Grant Site Principal Investigator	
Veronica Perez-Rosas	NA
Francisco Romo-Nava	NA
Matt Samocki	NA
Giselli Scaini	NA
Christopher Schneck	NA
Courtney Soule	NA
Nicholas Trapp	NA
Rob Vallentine	NA
Jennifer Vande Voort	Assurex:Other
Sandra Weiss	NA
Nolan Williams	Magnus, Otsuka, Neurawell,Sooma:Consultant
Justin Kaiser	NA

**OBTAIN YOUR
CERTIFICATE
HERE!**



How to Get Your Certificate

1. Go to nndc.cmecertificateonline.com
2. Click on the 2024 NNDC 16th Annual Conference link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com

2024 Annual Conference Poster Session

The posters listed below were submitted in the following categories:

Basic Science

This category features posters dealing with approaches (both biological and psychosocial) to understanding mood disorders, new or repurposed treatments and technologies, monitoring strategies with the potential to improve patient outcomes, or objective measures like biometrics, neuroimaging, bloodwork, or genetics.

Clinical Programs

Unified efforts are the best way to expedite technological innovation, dissemination of new information, and translation of research into clinical practice. Posters in this category showcase multidisciplinary programs, demonstrate the efficacy of collaborations beyond academic boundaries, or deal with clinical assessments like patient questionnaires, clinical diagnoses, or clinical interviews.

Poster Number, Submitter + Title

1-12 NNDC Task Groups

13 NNDC DEI Committee

Basic Science Posters

14 **Herpes Simplex Reactivation Triggers Symptom Exacerbation in Patients with Major Depressive Disorder**
Ehraz Anis - Van Andel Research Institute

15 **Women and Mood Disorders Task Group Momentum Award: Grant Proposal on Polygenic Risk Scores for Depression in Women**
Ritika Baweja - Penn State Health

16 **Peripheral Mitochondrial Changes to Superolateral Medial Forebrain Bundle Deep Brain Stimulation for Treatment-Resistant Depression**
Francisco Elielecio Rodrigues da Silva - UTHealth Houston

17 **Antidepressant-Induced Destabilization in Bipolar Illness Mediated by Serotonin 3 Receptor (5HT3)**
Rif S. El-Mallakh - University of Louisville

18 **Using the Timeline of Depression Onset to Explore Dimensions of Chronic Pain**
Eva Q. P. Gontrum - University of Utah

19 **Relationship Between Childhood Trauma and Resilience in a Mexican Population**
Maria Sarai Gonzalez - Universidad Autonoma de Nuevo Leon

20 **The Bioenergetic Compound Cyclocreatine Improves Depressive and Anxiety Symptoms in an Animal Model of SSRI-Resistant Depression at Altitude**
Shami Kanekar - University of Utah

21 **Depressive Symptoms and Hazardous Alcohol Consumption Predict Suicidal Behavior Among Patients with Bipolar Disorder**
Jasmin Leah Katz - Emory University

22 **Depressive and Anxiety Disorders in Disorders/Differences of Sex Development: Exploring the Effects of Prenatal Testosterone**
Behzad Sorouri Khorashad - University of Utah

23 **A Multifaceted Quality Improvement Project to Increase Rates Metabolic Monitoring of Lipids and Hemoglobin A1C/Glucose for Patients Prescribed Second-Generation Antipsychotics**
Christina C. Klein - University of Cincinnati & Lindner Center of HOPE

Basic Science Posters, continued

- 24 **Depressive Outcomes of Patients Receiving Ketamine Infusions for Pain**
Kalei Lopez - Mayo Clinic
- 25 **Exploring the Impact of Repetitive Transcranial Magnetic Stimulation on Suicidal Ideation in Psychiatric Patients: A Systematic Review**
Olga Lopez - Mayo Clinic
- 26 **Adverse Childhood Experiences and its Impact on Suicide Attempts in Mexican Patients with Bipolar Disorder**
Sofia Luna-Garza - Universidad Autonoma de Nuevo Leon
- 27 **Can Inflammatory Markers Predict Response to Swedish Massage Therapy in Patients with Generalized Anxiety Disorder?**
Ambika Maria - University of Utah
- 28 **The Relationship of Anxious Arousal with Treatment of Dysphoria Using VR Mindfulness and Two Accelerated TMS Protocols**
Austin M. Spitz - Florida State University
- 29 **Update on the National Network of Depression Centers Mood Outcomes Program: Focus on Adolescents Post-Covid**
Jason Straub - Johns Hopkins University

Clinical Programs Posters

- 30 **Retention, Service Disruptions, and Outcomes in Home-Based CBT for Perinatally Depressed Mothers with Low-Incomes**
Robert T. Ammerman - University of Cincinnati & Lindner Center of HOPE
- 31 **Assessing Behavioral and Mental Health Referral Orders in an Academic Health System: An Exploratory Quality Improvement Study**
Sarah Eyo Asuquo - University of Utah
- 32 **Healthcare Costs and Utilization in a Cohort of Adults Receiving Pragmatic Measurement-Based Psychiatric Treatment: Cross-Sectional and Quasi-Experimental Findings**
Tyson Barrett- Highmark Health
- 33 **Health Outcomes in a Cohort of Adults Receiving Pragmatic Measurement-Based Psychiatric Treatment: Cross-Sectional And Quasi-Experimental Findings**
Mason T. Breitzig - Penn State Health
- 34 **Breakthrough Discoveries for Thriving with Bipolar Disorder (BD²): Utilizing Shared Input to Design and Launch a Multi-Site Collaboration**
Veronica Corinne Beck - BD² / Milken Institute
- 35 **Phase II, Randomized, Dose-Finding Studies of The Novel NMDA Subunit 2B-Selective Negative Allosteric Modulator, Bi 1569912, in People Living with Major Depressive Disorder**
Heather Davidson - Boehringer Ingelheim Pharmaceuticals, Inc.
- 36 **Cognitive and Fine Motor Impairments in Depression: A Comparative Study with Implications for Treatment**
Ioanna Douka - University of Utah
- 37 **A Multidisciplinary Approach to Support Patients Experiencing Demoralization**
Lauren Elizabeth Eide - Mayo Clinic

Clinical Programs Posters, continued

- 38 **Three Distinct Pathways to First Episode Mania and Psychosis: Latent Class Analyses of Antecedent Psychopathology**
Metec Ercis - Mayo Clinic
- 40 **Developing an Anthropometric and Dietary Registry for Early Identification of Metabolic Risk in First-Time Outpatient Mental Health Service Users: Study Rationale and Preliminary Findings**
Manuel Gardea Resendez - Universidad Autonoma de Nuevo Leon
- 41 **Impact of PTSD, Trauma, and Cannabis Use on Depression and Anxiety Symptoms**
Weston Grove - UTHHealth Houston
- 42 **Challenges and Opportunities in Using Cognitive Screeners in Clinical Practice for Youth With Bipolar Disorder: Insights from NNDC Clinicians**
Rebekah S. Huber - University of Utah
- 43 **Impact of Weighted Multi-Gene Pharmacogenomic Testing on Hospitalization Rates in a Real-World Dataset of Patients with Major Depressive Disorder**
Holly L. Johnson - Myriad Genetics, Inc.
- 44 **PAPR: Psilocybin-Assisted Therapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider Covid-19 Related Depression and Burnout**
Benjamin Lewis - University of Utah
- 45 **Lithium and Covid-19: Infection Rates and Symptom Severity in Patients with Bipolar Disorder**
Carleigh A. Litteral - University of Louisville
- 46 **Association of Childhood Trauma with Inflammatory Biomarkers in the Pro-Inflammatory Phenotype of Major Depression**
Nicolas A. Nunez - University of Utah
- 47 **Combination of Transcranial Magnetic Stimulation and Ketamine in Treatment-Resistant Depression: A Literature Review**
Oluwatosin Omobolanle Arubuolawe - Olabisi Onabanjo University
- 48 **Enhancing Access to Care as well as Patient Education for Bipolar Disorder with Group Medical Visits / Shared Medical Appointments**
Sagar Parikh - University of Michigan
- 49 **Dual-Target Theta Burst rTMS in Patients with Methamphetamine Use Disorder Decreases Use and Depressive Symptoms in an Open-Label Pilot Clinical Trial**
Jackson R Richards - University of Iowa
- 50 **Seltorexant, Adjunctive to Antidepressants, in Adults with Major Depressive Disorder with Insomnia Symptoms: Results of a Double-Blind, Randomized, Placebo-Controlled Study**
Joseph M. Trombello - Janssen Research & Development, LLC
- 51 **Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses From SKYLARK, A 50 mg Placebo-Controlled Phase 3 Study**
Theresa Vera - Sage Therapeutics, Inc.

Clinical Programs Posters, continued

- 53 **COMP005 + COMP006: Example Approaches to Challenges in Randomized-Controlled Clinical Trials with Psychedelics**
Matthew Young - Compass Pathfinder Ltd
- 54 **Depressive Symptoms and Hazardous Alcohol Consumption Predict Suicidal Behavior Among Patients with Bipolar Disorder**
Jazmin Leah Katz - Emory University
- 55 **Developing a Treatment-Resistant Depression Consultation Program: Part I. Practical and Logistical Considerations**
Vitaliy L Voytenko - Western Michigan University
- 56 **Developing a Treatment-Resistant Depression Consultation Program: Part II. Assessment**
Jay C. Fournier - The Ohio State University

Congratulations to the...

2024 Young Investigator Travel Awards


- Ehraz Anis, MSc, PhD, Van Andel Research Institute | **Poster #14**
- Mason T. Breitzig, PhD, MPH, Penn State Health | **Poster #33**
- Mete Ercis, MD, Mayo Clinic | **Poster 38**
- Jasmin Leah Katz, MA, PhD Candidate, Emory University | **Poster #54**
- Christina Klein, PhD, MPH, University of Cincinnati & Lindner Center of HOPE | **Poster #23**
- Carleigh A. Litteral, graduate student, University of Louisville | **Poster #45**
- Sofia Luna-Garza, MD, Universidad Autonoma de Nuevo Leon (UANL) | **Poster #26**
- Jackson Richards, MD, PhD, University of Iowa | **Poster #49**
- Francisco Eliclecio Rodrigues da Silva, PhD, UTHealth Houston | **Poster #16**
- Austin Spitz, MS, Florida State University | **Poster #28**

Facility Map - Alumni House



	Dimensions	Sq. Ft.	Theatre	Banquet	U Shape	Classroom	Hollow Sq.
Entire Ballroom	115' x 49'	5,800	560*	320 224	75	360*	126*
Ballroom AB or BC	76' x 49'	3,724	360	96	60	264*	90*
Ballroom A, B, or C	38' x 49'	1,862	150		42	120	54

*May require outside furniture rentals for an additional cost.



	Dimensions	Square Ft.	Theatre	Banquet	U Shape	Classroom	Hollow Sq.
Boyer Conference Room	18' x 38'	540	48	16 36 72	18 27 36	18	24
Sorenson + Boyer	31' x 45'	1,395	72	NA	18	36	36
Executive Terrace Beehive	41' x 37'	1,517	120			72	42
Conference Room	15' x 30'	450	40			NA	20
Sorenson Boardroom	31' x 21'	650					


Conference table for 18

Facility Map - Alumni House



Dumke Reception Room

Dimensions	Sq. Ft.	Theatre	Banquet
27' x 53'	1,431	120	80
U shaped	Classroom	Hollow Sq.	
30	63	48	



Pugh Business Center/Lounge

Dimensions	Sq. Ft.	
47' x 12'	987	Conference table for 8, lounge & virtual studio office

Patel Conference Room

Dimensions	Sq. Ft.	
27' x 12'	324	Conference table for 16




Henriksen Conference Room

Dimensions	Sq. Ft.	Theatre	Banquet
27' x 53'	1,335	120	80
U shaped	Classroom	Hollow Sq.	
30	63	48	

Back Patio

Dimensions	Sq. Ft.	Theatre	Banquet
114' x 54'	5,213	120	120
U shaped	Classroom	Hollow Sq.	
48	108	54	



NNDC Upcoming Events



VIRTUAL + IN-PERSON OPTIONS!

SEPTEMBER 27-28, 2024
CHICAGO, IL

2024 NATIONAL NETWORK OF DEPRESSION CENTERS BEST PRACTICES FOR MOOD DISORDERS IN COLLABORATION WITH MAYO CLINIC



More information coming soon!

2025 APA RECEPTION: MAY 17

Los Angeles



Seeking NNDC Member Co-Hosts for the 3rd Annual APA Conference Reception

2025 NNDC ANNUAL CONFERENCE: SEPTEMBER 11-12, 2025



17th ANNUAL 2025 CONFERENCE


CO-HOSTED WITH THE UNIVERSITY OF CINCINNATI & LINDNER CENTER OF HOPE

More information coming soon!

LET'S CONNECT!



NEWS, EVENTS, UPDATES AND MORE!




GIVE US A FOLLOW!



WANT TO BE FEATURED?

Email Courtney Soule at csoule@nndc.org



LEARN MORE AT NNDC.ORG